Using blood tests to tailor treatment for lymphoma patients
Circulating tumor DNA guided de-escalation of frontline diffuse large B-cell lymphoma therapy
This study is looking at how a simple blood test can help doctors tailor treatment for people newly diagnosed with diffuse large B-cell lymphoma, so they can get the right amount of therapy to reduce side effects while still being effective.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11045782 on NIH RePORTER |
What this research studies
This research investigates how circulating tumor DNA (ctDNA) can be used to guide the treatment of patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). By analyzing ctDNA from blood samples, the study aims to identify patients who may benefit from a reduced treatment regimen, potentially decreasing side effects while maintaining effectiveness. The approach involves real-time assessment of molecular responses to therapy, which could lead to more personalized treatment plans. This innovative method seeks to improve patient outcomes by allowing for treatment de-escalation based on individual responses.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with newly diagnosed diffuse large B-cell lymphoma who are at an advanced stage and may be eligible for treatment de-escalation based on ctDNA analysis.
Not a fit: Patients with early-stage DLBCL or those who do not have detectable ctDNA may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to less intensive treatment for some lymphoma patients, reducing side effects while maintaining effective cancer control.
How similar studies have performed: While the use of ctDNA in DLBCL has shown promise in retrospective studies, this approach of real-time assessment for treatment de-escalation is novel and has not been extensively tested.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Cherng, Hua-Jay Jeffery — Columbia University Health Sciences
- Study coordinator: Cherng, Hua-Jay Jeffery
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.